Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hi-Tech Pharmacal through its ECR Pharmaceuticals division has re-launched Zolpimist Oral Spray (zolpidem tartrate) and DexPak Taperpaks (dexamethasone tablets).
Subscribe to our email newsletter
ECR has also divested its interest in non-core products like Hylase and Orbivan.
Hylase was divested for a one-time payment in January while Orbivan for $500,000 over two payments in March and an ongoing royalty stream.
ECR Pharmaceuticals president and CEO Cameron Durrant said that the company is executing against a clear strategy, part of which includes divesting or partnering non-core assets,while rigorously focusing on key assets, such as Bupap, Tussicaps, Zolpimist and Dexpak.